Paper39802403
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?
Wang W and 8 others. Genes Dis, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable? Papers, record 39802403. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39802403
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA186662 | NCI NIH HHS | United States | R01CA186662 | PubMed | NIH RePORTER |
| R01 CA214019 | NCI NIH HHS | United States | R01CA214019 | PubMed and NIH | NIH RePORTER |
References196
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27586230 | The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma. | Invest New Drugs | 2016 | https://conductscience.org/library/papers/27586230 | PubMed |
| 2 | 15720185 | p53-independent activities of MDM2 and their relevance to cancer therapy. | Curr Cancer Drug Targets | 2005 | https://conductscience.org/library/papers/15720185 | PubMed |
| 3 | 9419352 | Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. | Proc Natl Acad Sci U S A | 1998 | https://conductscience.org/library/papers/9419352 | PubMed |
| 4 | 34565342 | Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma. | BMC Cancer | 2021 | https://conductscience.org/library/papers/34565342 | PubMed |
| 5 | 2997622 | L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. | Nature | 1985 | https://conductscience.org/library/papers/2997622 | PubMed |
| 6 | 21862876 | Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. | Cell Cycle | 2011 | https://conductscience.org/library/papers/21862876 | PubMed |
| 7 | 21876694 | Targeting angiogenesis for controlling neuroblastoma. | J Oncol | 2012 | https://conductscience.org/library/papers/21876694 | PubMed |
| 8 | 35018218 | Induction of serine hydroxymethyltransferase 2 promotes tumorigenesis and metastasis in neuroblastoma. | Oncotarget | 2022 | https://conductscience.org/library/papers/35018218 | PubMed |
| 9 | 29311926 | Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen. | Front Pharmacol | 2017 | https://conductscience.org/library/papers/29311926 | PubMed |
| 10 | 14751837 | Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. | Ann N Y Acad Sci | 2003 | https://conductscience.org/library/papers/14751837 | PubMed |
| 11 | 2842250 | Confirmation of the assignment of MYCL to chromosome 1 in humans and its position relative to RH, UMPK, and PGM1. | Genomics | 1988 | https://conductscience.org/library/papers/2842250 | PubMed |
| 12 | 27394681 | Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. | J Control Release | 2016 | https://conductscience.org/library/papers/27394681 | PubMed |
| 13 | 19111882 | Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. | Cancer Cell | 2009 | https://conductscience.org/library/papers/19111882 | PubMed |
| 14 | 31869746 | Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors. | Transl Oncol | 2020 | https://conductscience.org/library/papers/31869746 | PubMed |
| 15 | 31988297 | Lipid desaturation-associated endoplasmic reticulum stress regulates MYCN gene expression in hepatocellular carcinoma cells. | Cell Death Dis | 2020 | https://conductscience.org/library/papers/31988297 | PubMed |
| 16 | 29527331 | Targeting oncogenic Myc as a strategy for cancer treatment. | Signal Transduct Target Ther | 2018 | https://conductscience.org/library/papers/29527331 | PubMed |
| 17 | 34003079 | MYCN amplification levels in primary retinoblastoma tumors analyzed by Multiple Ligation-dependent Probe Amplification. | Ophthalmic Genet | 2021 | https://conductscience.org/library/papers/34003079 | PubMed |
| 18 | 26497213 | Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. | Oncotarget | 2015 | https://conductscience.org/library/papers/26497213 | PubMed |
| 19 | 33034426 | The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma. | Cancer Med | 2020 | https://conductscience.org/library/papers/33034426 | PubMed |
| 20 | 25271708 | The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. | Nat Commun | 2014 | https://conductscience.org/library/papers/25271708 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41328404 | Dual Regulation and Clinical Application of miR-34 in Virus-Related Tumors Through Anti-Viral Immunity and Tumor Suppression. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/41328404 | PubMed |
| 41228232 | Masters of Gene Expression: Transcription Factors in Pediatric Cancers. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228232 | PubMed |
| 40317918 | Delving Into Retinoblastoma Genetics: Discovery of Novel Mutations and Their Clinical Impact: Retrospective Cohort Study. | Cancer Med | 2025 | https://conductscience.org/library/papers/40317918 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MDM2 | 4193 | PubTator's text mining | https://conductscience.org/library/genes/4193 | NCBI Gene |
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 | NCBI Gene |
| MYCN | 4613 | PubTator's text mining | https://conductscience.org/library/genes/4613 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39802403
GET https://conductscience.org/api/papers/v1/39802403/references?page=2